Form 10-Q PLIANT THERAPEUTICS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)
August 8, 2024 9:30 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $32.00 price target on Pliant Therapeutics (NASDAQ: PLRX).
The analyst comments "We remain Buy Rated on PLRX following their 2Q24 update. The Ph2/3 BEACON-IPF trial remains the key driver for shares over the next 12-18... More
